Phosphorylation of threonine 638 critically controls the dephosphorylation and inactivation of protein kinase Cα  by Bornancin, Frédéric & Parker, Peter J.
1114 Research Paper
Phosphorylation of threonine 638 critically controls the
dephosphorylation and inactivation of protein kinase Ca
Frédéric Bornancin* and Peter J. Parker
Background: It has been widely reported that multisite phosphorylation plays an
essential role in the regulation of protein kinases. However, our understanding of
how these events modify protein function in vitro and in vivo is poorly
understood. Protein kinase C (PKC) affords an interesting example of how
phosphorylation control is coupled to effector control. PKC is acutely regulated
by the second messenger diacylglycerol; however, it is also known to undergo
multisite phosphorylation. Previously, we and others have shown that one site in
the ‘activation loop’ of PKCa (a threonine residue at position 497; T497) and
PKCb (T500) is essential for the catalytic competence of these proteins. More
recently, a carboxy-terminal site (T638 in PKCa) has been implicated. In this
report, we investigate the role of this site and its interaction with the catalytic
core site.
Results: We have analyzed mutant PKCa proteins, in which amino-acid
substitutions were made at the T638 site, and shown that phosphorylation at this
site affects the conformation of the protein, as judged by thermal stability, and
sensitivity to oxidation, trypsin and phosphatase treatment. This supersensitivity
to dephosphorylation in vitro was also seen in an agonist-dependent context in
vivo. We have also shown that phosphorylation of this site is not essential for
catalytic activity of the purified protein. The molecular basis of the control
operating through the T638 site was provided by the evidence of a functional
interaction with the previously described catalytic core site, T497. This inter-
relationship was further established by the demonstration that the E497 mutant
protein had a thermal instability and phosphatase supersensitivity similar to that
of the A638 and E638 mutants.
Conclusions: The T638 phosphorylation site is not required for the catalytic
function of PKCa per se, but serves to control the duration of activation by
regulating the rate of dephosphorylation and inactivation of the protein. This is
achieved through the cooperative interaction between the T638 and T497 sites;
if either of these residues is not phosphorylated, the protein is supersensitive to
phosphatase action. This model of PKCa function is likely to be of general
significance to the protein kinase superfamily, where similarly juxtaposed sites
exist. We conclude that dephosphorylation of PKCa, and, by inference, other
protein kinases, is regulated by multisite phosphorylation.
Background
Protein kinase Cs (PKCs) are a family of serine/threonine
protein kinases that are regulated through agonist-induced
hydrolysis of membrane phospholipids and are considered
to play critical roles in many signal-transduction pathways
[1–4]. The binding of lipid second messengers to PKC
triggers a conformational change that displaces the
enzyme’s autoinhibitory domain, thereby exposing the
substrate-binding region [5]. However, in order to phos-
phorylate its substrates, the kinase first has to be rendered
catalytically competent. Growing evidence supports a role
for phosphorylation in priming PKC function. In protein
kinases, a region linking the two conserved subdomains
VII and VIII of the catalytic domain [6] has been identi-
fied as an ‘activation loop’ or ‘phosphorylation lip’ [7],
according to the known crystal structures of protein kinase
A [8], cyclin-dependent protein kinase [9] and mitogen-
activated protein kinase [10]. For many proteins, phos-
phorylation in this region is critical for function [11–17]. A
threonine residue at position 497 (T497) in the activation
loop of PKCa has been identified as a critical site for per-
missive activation — a process that generates a kinase that
can be activated by second messengers [13,18]; a corre-
sponding site (T500) is present in PKCb2 [16]. Early
Address: Imperial Cancer Research Fund, PO Box
123, Lincoln’s Inn Fields, London WC2A 3PX, UK.
Present address: *Institut de Recherches Servier,
125 Chemin de Ronde, 78290 Croissy-sur-Seine,
France.
Correspondence: Peter J. Parker
Received: 7 May 1996
Revised: 18 July 1996
Accepted: 18 July 1996
Current Biology 1996, Vol 6 No 9:1114–1123
© Current Biology Ltd ISSN 0960-9822
studies on human breast cancer cells [19] and treatment in
vitro with phosphatases [20] have suggested that a PKC
kinase is responsible for phosphorylation of this site.
In addition to the permissive phosphorylation at T497 in
the activation loop, at least one other functionally relevant
phosphorylation takes place in the PKCa molecule, at
T638, a site now known to be phosphorylated in vivo [21].
It has been reported that phosphorylation at the equiva-
lent site in PKCb1 (T642) and PKCb2 (T641) is essential
for activation [21,22]. Like the PKCa mutants lacking
phosphorylated T497 [13,18], a PKCb1 mutant lacking
phosphorylated T642 is inactive [22]. These studies
prompted us to unravel the role of both phosphorylations
— at the activation loop (T497) and the carboxy-terminal
T638 site — in the control and function of PKCa.
Here, we show that phosphorylation at T497 and T638 are
both relevant to the function of PKCa, but in different,
albeit complementary, ways. Phosphorylation at T497 is
required for catalytic activity, whereas phosphorylation at
T638 is not. Phosphorylation at T638, however, controls
the dephosphorylation and inactivation of the enzyme.
Furthermore, phosphate groups at both sites cooperate to
stabilize the active conformation. These studies, and
further proteolytic analysis, suggest a model, which ratio-
nalizes interactions between the catalytic domain and the
carboxy-terminal part of the PKCa molecule; this is likely
to be of general importance for other members of the
protein kinase superfamily.
Results
One-step purification of PKCa
To assess the properties of the PKCa phosphorylation site
mutants, we established a simplified purification proce-
dure that was specific for the recombinant protein
expressed in mammalian cells. This was achieved by  intro-
ducing a histidine tag either at the amino terminus (N-His)
or within the hinge region (hinge-His) of PKCa, which
permitted one-step purification on nickel–agarose. As
shown in Figure 1 for the purification of wild-type N-His
PKCa, this procedure yielded a highly purified preparation
free of the endogenous PKC isotypes. The functional
attributes of N-His PKCa and hinge-His PKCa are
entirely consistent with those recorded for purified wild-
type PKCa (data not shown; but see below). We used
N-His PKCa for the mutant analyses described here.
Expression and purification of PKCa phosphorylation site
mutants
In order to analyze the contribution of phosphorylation at
position 638, mutations were designed that either pre-
vented phosphorylation (the alanine substitution A638), or
might partially mimic phosphorylation by introduction of a
carboxyl side chain (glutamic acid substitution E638). The
histidine-tagged mutant proteins were expressed in COS-1
cells and purified on nickel–agarose, as illustrated in the
western blot shown in Figure 2. The mutant proteins were
efficiently produced in COS-1 cells, although compared
with wild-type PKCa, both mutants were less soluble in
detergent. The purified proteins that eluted from
nickel–agarose migrated predominantly as 80 kDa species;
faster migrating (dephosphorylated) forms were present in
the insoluble fraction and the unbound material. The
unbound 80 kDa species present in all the samples repre-
sents the endogenous COS-1 cell PKCa. The specific
activities of the purified proteins were determined and
found to be virtually the same as wild-type PKCa (Fig. 2;
see also Table 1). Thus, phosphorylation at the T638 site is
not essential for activity.
The activities of the PKCa T638 mutants are unstable 
in vitro
The modest effects of mutations at the T638 site on solu-
bility and phosphorylation in vivo (as judged by altered
migration), suggested that this site plays a subtle role in
the regulation of PKC. To investigate this, we carried out
a more detailed analysis of the properties of the T638
mutants. The results of this analysis revealed that, in the
absence of phosphate at the T638 site, the protein under-
went rapid thermal inactivation and was sensitive to oxida-
tion, as detailed below.
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Figure 1
Purification of histidine-tagged PKCa after transient expression in COS-1
cells. COS-1 cells, 48 h after transfection with the cDNA encoding the wild-
type histidine-tagged PKCa cDNA, were lysed in 1 % Triton X-100 and
purified as described in Materials and methods. Lane 1 shows the insoluble
fraction; lane 2 shows the Triton-soluble extract. This extract was allowed to
interact with nickel–agarose beads. Lane 3 shows the Triton-soluble proteins
that did not bind to nickel–agarose. Following several washes, bound proteins
were eluted with 100 mM imidazole; lane 4. The figure shows a Coomassie-
stained 10 % polyacrylamide gel, after electrophoresis of comparable
amounts of samples. The positions of PKCa and the molecular weight
markers (in kDa) are indicated.
1 42 3
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Following storage of the purified A638 mutant at 4 °C, it
was noted that its activity decayed, whereas the activity of
wild-type PKCa was essentially stable. This inactivation
was greatly exaggerated at higher temperatures (Fig. 3a).
At 25 °C, the A638 mutant lost activity, with a half-life of
less than 10 minutes. In contrast, only about 10 % of the
wild-type PKCa activity was lost after 30 minutes under
identical conditions. Notably, the E638 mutant, where
the glutamic acid may partially mimic phosphorylation at
this site, showed intermediate stability, with a half-life of
approximately 25 minutes. Western analysis of these
incubated proteins revealed that as well as the observed
inactivation of the mutants, there was an accumulation of
more rapidly migrating PKCa species (Fig. 3b). This
might reflect dephosphorylation and/or partial proteolysis
(see below). No such alterations took place for the wild-
type PKCa.
In order to assess the role of contaminating phosphatases in
the inactivation and altered migration, the A638 mutant
was incubated in the presence or absence of the phos-
phatase inhibitor microcystin. As shown in the upper part
of Figure 3c, microcystin (lane 4) prevented the altered
migration of the mutant protein, indicating that the more
rapidly migrating species were dephosphorylated forms. In
parallel, b-mercaptoethanol was tested for its potential
ability to protect against inactivation. As shown in the
lower part of Figure 3c, neither b-mercaptoethanol (corre-
sponding to lane 3 in the upper panel) nor microcystin (cor-
responding to lane 4) prevented inactivation under these
conditions (but see below). Although microcystin entirely
blocked dephosphorylation, its inability to prevent inacti-
vation indicated that a distinct mechanism was responsible
for activity loss. Furthermore, the maintenance of the
Figure 2
Expression and purification of PKCa 638 site mutants. Wild-type PKCa
(T638) and proteins with carboxy-terminal mutations (A638 and E638)
were transiently expressed in COS-1 cells and purified as in Fig. 1. High-
resolution SDS–PAGE (the region between the 97.4 kDa and 66.2 kDa
markers is shown) was followed by western-blot analysis, using a
polyclonal antibody raised against the carboxyl terminus of PKCa; the
western blots in all panels were processed together. Direct comparison
can be made for all proteins, because equivalent amounts of cells (based
upon protein assay of the respective Triton-soluble fractions) were loaded
in every lane. In order to detect low amounts of PKCa, the membranes in
the lower two panels were exposed for 5-times longer than the upper two
panels. The endogeneous PKCa, which is the only form seen in the
vector-transfected control, does not bind nickel–agarose, and is indicated
with an arrow in the third panel. The specific activities, shown under the
bottom panel for each PKCa preparation, were measured in vitro on the
PKCa mutants purified on nickel–agarose. Histone was used as a
substrate, with mixed micelles of Triton X-100, phosphatidylserine, and
TPA, in the presence of calcium, as described in Materials and methods.
Activity of the wild-type enzyme was in the range of
5–20 mmol mg–1min–1 at 25 °C. In the absence of cofactors, there was
no activity associated with either the wild-type or any of the mutant
proteins (data not shown). Values shown represent the mean of five
(E638, A638) independent determinations (see also Table 1).
Insoluble
Triton-
soluble
Unbound
Eluted
PKCα site 638 
  Control         T        E        A
    100      71      74Specific
activity (%)
Table 1
The specific activities of activation-loop and T638 site mutants.
Activation loop Carboxy-terminal Relative specific activity
494, 495, 497 638 (mean ± SEM)
TTT* T* 100
TTT E 71 ± 17
TTT A 74 ± 13
TTE T 22 ± 3
TTE E 17
TTE A < 0.2
AAE T 5.5 ± 2
AAE E < 0.2
AAE A < 0.2
The mutant proteins indicated by the amino acids at residues 494, 495,
497 and 638, were transiently expressed in COS-1 cells and purified by
nickel–agarose affinity chromatography, as described in Materials and
methods. The activities were determined directly using histone as a
substrate (see Materials and methods). These activities are expressed as
a function of PKCa antigen and presented relative to the wild-type
activity (5–20 mmol min–1 mg–1) determined in parallel in each of five
(E638, A638), three (E497) or two (AAE) independent experiments.
Values are means and SEM. For the TTE/E mutant, specific activity was
determined in one experiment only. In the case of the mutants TTE/A,
AAE/E and AAE/A, no antigen was recovered upon affinity purification on
nickel–agarose, and activities were determined for the unpurified
proteins. *Wild-type protein.
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80 kDa antigen in the presence of b-mercaptoethanol and
microcystin demonstrated that proteolysis was not respon-
sible for loss of activity. It should be noted that b-mercap-
toethanol had a protective effect upon antigen loss
(compare Fig. 3c, lanes 2 and 3), and slowed the rate of
dephosphorylation.
Protection of PKCa T638 mutants from inactivation 
The subtle effects of b-mercaptoethanol suggested the
possible involvement of oxidation in one pathway of
PKCa inactivation. At lower temperatures (below 22 °C),
the effects of the reducing agents were more apparent. At
4 °C, b-mercaptoethanol (data not shown) and dithiothre-
itol (DTT) protected the PKCa A638 mutant for several
hours (Fig. 4a). Wild-type PKCa remained active in the
presence and absence of reducing agents (data not shown).
This protective effect indicated that the sulphydryl group
of a critical cysteine residue is exposed in the A638 mutant
and is sensitive to oxidation. In protein kinase A (PKA),
alkylation of C199 induces inactivation [23–26]; this cys-
teine residue lies close to a threonine at position 197, the
activation loop phosphorylation site in PKA. In PKCa, the
equivalent phosphorylation site (T497) is similarly juxta-
posed with a cysteine residue (C499). The binding of
adenylyl nucleotides to the ATP-binding site of PKA pre-
vents alkylation of C199 [23,24]. To determine whether
the sensitive sulphydryl in PKCa behaved similarly, we
investigated the effects of nucleotides on its inactivation.
We found that Mg–ATP and Mg–ADP could fully protect
PKCa A638 from inactivation at 25 °C (Fig. 4b); Mg–AMP
or ATP alone afforded no protection. It should be noted
that autophosphorylation of PKCa is not seen in the
absence of lipids; hence, under these conditions, Mg–ATP
was not ‘protecting’ by increasing phosphorylation. This
was further suggested by the finding that the A638 mutant
was also fully protected by Mg–ADP. The sulphydryl sen-
sitivity is consistent with C499 being more sensitive to
oxidation in PKCa A638 than in the wild-type protein,
indicating that lack of phosphorylation of T638 leads to
exposure of this cysteine.
PKCa T638 mutants are supersensitive to protein
phosphatases both in vitro and in vivo
The dephosphorylation of PKCa A638 but not wild-type
PKCa (see Fig. 3b) suggested that this mutant might be
more sensitive to phosphatases — that is, its sites were
more available than those of the wild-type protein. Protein
phosphatase 1 (PP1) has been shown to dephosphorylate
and inactivate PKCa [20] and PKCb [27] in vitro. In order
to avoid any contribution from contaminating phos-
phatases, the dephosphorylation of wild-type PKCa and
PKCa A638 was tested with excess PP1 and with purified
PKCa proteins bound to nickel–agarose (Fig. 5). Under
conditions where the first fast-migrating species of wild-
type PKCa was just visible (lane 2), PKCa A638 was fully
shifted to its fastest migrating form (lane 4). The E638
mutant was analyzed in parallel and was also supersensi-
tive to PP1 (compare lanes 5 and 6). Thus, lack of phos-
phate at the T638 site correlates with sensitivity to
dephosphorylation at the remaining sites.
Recent studies from this laboratory have shown that, in
vivo, dephosphorylation of PKCa takes place in a mem-
brane compartment following activation by TPA (12-O-
tetradecanoyl phorbol-13-acetate; G. Hansra, F.B., R.
Whelan and P.J.P., unpublished observations). In order to
determine the sensitivity of the A638 mutant in vivo, its
dephosphorylation was monitored by altered migration fol-
lowing treatment of transiently transfected COS-1 cells
with TPA. The data in Figure 6 show a profound difference
Figure 3
The A638 and E638 PKCa mutants are
thermolabile. (a) Purified wild-type PKCa and
the A638 and E638 mutants were assayed for
their residual kinase activity following
incubation at 25 °C for the times indicated. The
kinase activity was assayed immediately after
the pre-incubation period. Activity values shown
are the mean of duplicates. (b) SDS–PAGE
followed by western blot, of the same partially
purified PKCa samples used in (a), after 0 or
30 min at 25 °C. (c) A sample of purified PKCa
A638 was kept on ice (lane 1, control) or
incubated at 25 °C for 30 min in the absence
(lane 2) or presence of 5 mM b-
mercaptoethanol (lane 3), or 5 mM b-
mercaptoethanol and 10 mM microcystin (lane
4). Samples were then assayed for kinase
activity (lower panel) or analyzed by high
resolution SDS–PAGE followed by
immunoblotting (upper panel). The data shown
are representative of three similar experiments.
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between wild-type PKCa and the PKCa A638 mutant.
The dephosphorylation of the mutant started (as judged by
its migration) no later than 5 minutes after the addition of
TPA, and by 15 minutes, the entire pool of A638 had been
converted into its fastest running species. The E638
mutant was tested in parallel and behaved in essentially the
same way; dephosphorylation in this case was complete by
30 minutes (data not shown). In contrast, treatment with
TPA for 1 hour did not lead to significant dephosphoryla-
tion of wild-type PKCa. In conclusion, the absence of
phosphate at T638 sensitizes PKCa to phosphatases both
in vitro and in vivo
Sensitivity of the A638 mutant to proteolysis 
The data above are consistent with the notion that phos-
phorylation at the T638 site induces a closed conformation
of PKCa; conversely, lack of phosphate at this site favours
an open conformation (see Discussion). To test potential
conformational differences, trypsin sensitivity was com-
pared for the wild-type and A638 PKCa proteins. Wild-
type PKCa showed a characteristic, time-dependent loss
of full-length antigen with a concomitant, transient accu-
mulation of a 47 kDa catalytic domain fragment (Fig. 7).
In contrast, the A638 PKCa mutant was very rapidly
degraded by trypsin, without any significant accumulation
of an immunoreactive 47 kDa species.
Functional interaction between T638 and T497 sites
The properties of the T638 site, in particular the effects of
ATP on stability and on protecting the cysteine residue
from oxidation, indicated that there may be an interaction
between this carboxy-terminal region and the catalytic
core, and that this interaction underlies the mechanism by
which T638 phosphorylation controls these properties. In
order to investigate this issue, we determined how this
site operates in the context of alterations to the T497 site
in the catalytic core; it has been established that the latter
is essential for activity. Because alanine substitution at
position 497 renders the protein completely inactive [18],
we tested mutant proteins with glutamic acid substitu-
tions, with or without alterations to the proximal threonine
Figure 4
Increased sensitivity of PKCa A638 to
oxidation and protection by nucleotides. (a) A
sample of purified PKCa A638 was assayed
for kinase activity immediately after elution from
nickel–agarose (t = 0). The sample was split
into two aliquots, one of which was
supplemented with 5 mM DTT. Both samples
were kept on ice and assayed for residual
kinase activity after the times shown. The graph
shows the time course of the activity of the
sample with no added DTT, plotted as a
function of the activity in the presence of DTT.
There was no activity loss in the sample
supplemented with DTT during the course of
the experiment (data not shown). (b) A sample
of purified PKCa A638, supplemented with
10 mM microcystin, was incubated at 25 °C for
30 min in the presence (+) or absence of one
or more of the following: 5 mM MgCl2, 5 mM
EDTA, 50 mM ATP, ADP or AMP. A control
treatment was also included, where ATP was
added at t = 30 min rather than t = 0 min (–/+).
After the incubation, activity was measured and
compared to that of an aliquot of the same
sample kept on ice, without any addition
(100 %). Values shown represent the mean of
two or three independent measurements (+
S.E.). ATP was also effective at 20 mM, which
is around the Km value for PKCa [41]; AMP
was ineffective, even at 1 mM (data not shown).
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Figure 5
Increased sensitivity of PKCa A638 and E638 to PP1 in vitro. Wild-
type PKCa and the A638 or E638 mutants were purified after transient
expression in COS-1 cells, but were not eluted from nickel–agarose.
An equal volume (30 ml) of PP1 dialysis buffer (see Materials and
methods) or PP1 (100 units ml–1) was added to these nickel–agarose-
bound PKC samples. The mixed sample was diluted twice in PKC-
purification buffer (see Materials and methods) and the reaction was
allowed to proceed for 2 h at 22 °C with continuous stirring. Samples
were then subjected to SDS–PAGE and immunoblotting, as above.
+ ++ – ––
Wild-type A638 E638
PP1
1	 2	 3	 4	 5	 6
Research Paper  Control of PKCa by multisite phosphorylation Bornancin and Parker    1119
residues, which further compromise activity. As indicated
in Table 1, mutation of the activation-loop site sensitizes
the protein mutated at the 638 site to loss of activity.
Thus, although both the TTE/T and AAE/T PKCa
mutants showed residual activity (23 % and 6 % of wild-
type PKCa, respectively), when combined with an alanine
mutation at position 638, the proteins were inactive.
These observations demonstrate that there is a functional
interaction between the catalytic core site (residue 497)
and the carboxy-terminal site (residue 638). In view of the
properties of the T638 phosphorylation site mutants
described above, and the interaction between the T638
and T497 sites, it was pertinent to determine whether
these properties were local (related to T638 only), or global
(related to T638 and T497). To this end, the activity of the
E497 mutant was assessed for thermal stability and phos-
phatase sensitivity. Like PKCa A638, PKCa E497 was
thermally unstable (Fig. 8a) and had a half-life of less than
30 minutes at 25 ºC. PKCa E497 was also much more sen-
sitive to PP1 than wild-type PKCa (Fig. 8b). Furthermore,
when the E497 mutant was transiently expressed in COS-1
cells, TPA treatment for 15–30 minutes induced its rapid
dephosphorylation (Fig. 8c). Thus, the activation-loop
mutant E497 behaved like the carboxy-terminal mutant
A638 (or E638), consistent with the functional interaction
identified for these phosphorylation sites.
Discussion
The evidence presented here demonstrates that phos-
phorylation at the T638 site in PKCa has no effect upon
catalytic activity in its own right, but acts to control the
sensitivity of the protein to dephosphorylation and inacti-
vation. This effect is readily observed in vitro, with PP1,
and in vivo, following stimulation with TPA. The molecu-
lar basis of this control is reflected in the properties of the
638 site mutants and their functional relationship to the
catalytic core phosphorylation site (T497). Thus, the
thermal inactivation, oxidation sensitivity, trypsin sensitiv-
ity and phosphatase supersensitivity are all compatible
with the view that phosphorylation at position 638 stabi-
lizes a ‘closed’ protein conformation (see model in Fig. 9),
in which the phosphorylation sites and sensitive cysteine
are not exposed to phosphatases and oxidants, respec-
tively. The finding that mutations at this carboxy-terminal
site and the catalytic core site (T497) act cooperatively to
cause loss of activity, implies that the closed conformation
involves the interaction between the carboxy-terminal
region and the catalytic core. This supposition is strongly
supported by the finding that the E497 mutant, like the
E/A638 mutants, is thermolabile and supersensitive to
PP1 in vitro and similarly supersensitive to agonist-
induced dephosphorylation in vivo.
Previous studies on the role of the 642 site in PKCb (the
equivalent of the 638 site in PKCa), using site-directed
mutagenesis, had indicated that phosphorylation of this
site is required for catalytic activity [22]. A similar conclu-
sion was reached by differentially dephosphorylating  the
purified protein [21]. These observations contrast with the
current data, which demonstrate no intrinsic requirement
for the equivalent phosphorylation event in PKCa.
Although this difference may reflect the analysis of distinct
PKC isotypes, it seems more probable that there is a
common process involved. The most likely explanation for
the different interpretations is that little consideration has
Figure 6
TPA induces rapid dephosphorylation of the PKCa A638 mutant in
vivo. After 30 h of transient expression, COS-1 cells expressing wild-
type PKCa or the A638 mutant were treated with TPA for up to
60 min, as described in Materials and methods. Cells were then lysed
in the presence of 1 % Triton X-100 and centrifuged. The Triton-
soluble extracts are shown after SDS–PAGE and immunoblotting.
There was no detectable PKCa in the Triton-insoluble fraction (data
not shown).
0 5 15 30 60
Wild-type
A638
TPA treatment (min)
 
Figure 7
A638 PKCa is hypersensitive to proteolysis. Wild-type and A638
PKCa were purified as described in Materials and methods. The
proteins were subjected to limited proteolysis with trypsin for the times
indicated. Proteins were then separated on 12.5 % SDS–PAGE gels
and immunoblotted for PKCa using a carboxy-terminal-reactive serum.
In both panels, the intact PKCa (80 kDa) is indicated by an arrowhead.
The catalytic domain fragment (47 kDa) generated from wild-type
PKCa is indicated by the arrow.
0    1     3   10 0    1     3   10Time (min)
Wild-type A638
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previously been taken of the dephosphorylation of PKC in
vivo and the thermal inactivation of the dephosphorylated
protein in vitro. The apparent inactivity and insolubility of
the PKCb mutant A642 is entirely consistent with the
accumulation of the dephosphorylated inactive form; thus,
as shown here for PKCa, this PKCb mutant is probably
supersensitive to dephosphorylation.
An acidic residue at position 638 produces a PKCa mutant
with a phenotype intermediate between that of wild-type
and A638 PKCa. This implies that such acidic mutations
only partially mimic phosphorylation. Similar partial
effects are seen for mutations at the T497 site (the E497
mutant has only 22 % of the activity of wild-type protein).
This compromised activity provided the means by which a
functional interaction between the T497 and T638 sites
could be demonstrated. Thus, in the context of an E497
mutation, the requirement for phosphorylation at the 638
site becomes more stringent. The mechanism of this inter-
play between sites probably involves a physical association
between the carboxy-terminal domain and the catalytic
core. This conclusion corroborates structural studies,
which propose that the carboxy-terminal region wraps
across the catalytic core with the phosphate in the 638 site
making contact with a basic cluster in the smaller, upper
lobe of the kinase domain [28].
Empirical evidence for the carboxyl terminus ‘masking’
the activation loop of PKCa is provided by the finding that
thiol-reducing agents are able to inhibit inactivation of the
Figure 8
Similarities between PKCa proteins with
mutations in the activation loop (E497) and
the carboxyl terminus (A638), both in vitro
and in vivo. (a) The thermolability of the
PKCa E497 mutant compared with that of
A638 and wild-type PKCa was determined
as described in Fig. 3a. After 30 min at
25 °C, the activity of PKCa E497 had
decayed by more than 50 % (data not
shown). (b) In vitro treatment of E497, A638
and the wild-type PKCa with PP1 was
performed as described in Fig. 5, except that
PKCa was eluted from nickel–agarose. A
time course was performed up to 120 min.
This figure shows the 30 min time point, after
SDS–PAGE and immunoblotting. At
t = 120 min, the wild-type enzyme had not yet
been dephosphorylated, whereas the
dephosphorylation of E497 had gone to
completion (data not shown). (c) The E497
mutant was treated with TPA in vivo, and
analyzed as described in Fig. 6.
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Figure 9
Model for the role of phosphorylation in
determining contacts between the catalytic
domain and the carboxyl terminus of PKCa.
Wild-type PKCa in its latent state has two
conformers in dynamic equilibrium; in the closed
conformation, the active site in the conserved
(C3/C4) region of the catalytic domain and the
carboxy-terminal part of the variable (V5) region
of PKC, interact; in the open conformation they
do not interact. When both T497 in the active
site and T638 in the V5 domain are
phosphorylated (red), PKCa essentially remains
in the closed conformation. The sulphydryl
group (SH) of C499 is buried and the protein is
resistant to phosphatases. If PKC lacks
phosphate on either T638 or T497 (whether as
a consequence of not being phosphorylated, or
being dephosphorylated), the equilibrium is
shifted towards the open conformation. In that
state, other phosphorylation sites in the protein
are accessible to phosphatase attack, the
sulphydryl group of C499 is exposed, and the
protein inactivates rapidly in vitro. Reg,
regulatory domain; Cat, catalytic domain.
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A638 mutant. This raises the possibility that a cysteine
side chain critical for activity becomes exposed; this is
reminiscent of PKA. In this protein, two cysteine residues
can be covalently modified, and for one of them, C199,
this leads to loss of activity [23–26]. This cysteine happens
to lie in the activation loop of PKA, just two residues away
from the critical phosphorylation site, T197. Several
studies, including the solution of the crystal structure of
PKA [8], have shown that C199 is near the active site, next
to the g-phosphate of ATP. PKCa also contains an equiva-
lent cysteine residue (C499), located similarly in the acti-
vation loop. We have shown that ADP and ATP prevent
inactivation of the A638 mutant. In a comparable manner,
ATP protected C199 in PKA from sulphydryl-reactive
agents, thereby preventing loss of activity [23,24,26]. One
interpretation that is consistent with these findings is that
in the A638 mutant, C499 is exposed and readily oxidised,
whereas in the wild-type protein it is buried.
The two phosphorylation sites analyzed in this study are
well conserved in the PKC superfamily. All PKC isotypes
identified so far, together with the recently identified
PRK family (protein kinase C-related kinases) [29,30],
contain this pair of phosphorylation sites equidistant from
each other. Outside the PKC superfamily, a similar phos-
phorylation pattern can also occur. For example, as for
PKC, the distance between the two sites is conserved in
PKA, where the phosphorylated residues are T197 (activa-
tion loop) and S338 (carboxyl terminus) [31–33]. The
crystal structure of PKA indicates that S338 is in close
proximity to the ATP-binding region [8]. A similar loca-
tion of T638 in the structure of wild-type PKCa would be
consistent with the observation that Mg–ATP can fully
protect the A638 mutant from inactivation. In PKA, stabi-
lization of the active structure through phosphorylation of
S338 has not been documented; however the carboxyl
terminus of PKA contains many acidic residues in the
neighbourhood of S338, which might already provide a
substantial contribution towards anchoring the carboxyl
terminus appropriately.
This study provides the first evidence of dephosphoryla-
tion as an important means of regulating PKC in vivo. It
has been shown that dephosphorylation of a defined site
in the active, membrane-associated PKC molecule is a
rate-limiting step leading to exposure and dephosphoryla-
tion of other sites. Serine 657, the third phosphorylation
site in the kinase domain of PKCa [21], seems to be one
of the sites cooperatively uncovered and dephosphory-
lated (F.B. and P.J.P., unpublished observations). A site
equivalent to S657 is also phosphorylated in vivo in PKCb
[21,34], and turns out to be well conserved not only in the
PKC family, but also in proteins like S6 kinase (p70s6k), in
which the distance between this site and the catalytic core
is the same as that for PKCa. In p70s6k, the dephosphory-
lation of this site is the principal event in the inactivation
induced by the immunosuppressive agent rapamycin [35].
The properties and the mechanism of dephosphorylarion
control proposed here for PKCa is likely to be of general
significance to p70s6k and other protein kinases that retain
phosphorylation sites in their equivalent carboxy-terminal
regions. The prediction is that the phosphorylation state
of these carboxy-terminal sites will affect the dephospho-
rylation of the catalytic core sites in the activation loops,
thus controlling the activities of the proteins.
Conclusions
The data presented here provide the basis for a model of
PKCa action, wherein newly synthesised PKCa accumu-
lates phosphate in multiple sites, including residue 497,
which is essential for activity. On agonist-dependent acti-
vation at the membrane, the protein is dephosphorylated,
and the rate of dephosphorylation of the active form is
tightly controlled by the extent of phosphorylation of the
T638 site. Agents that influence the steady-state level of
T638 phosphorylation will have a marked effect upon the
maintenance of active, membrane-associated PKC.
Materials and methods
Mutagenesis
The cDNA sequence of bovine PKCa [36] was modified by introducing
six histidine codons at the third codon after the initiator methionine
codon, producing N-His PKCa. To this end, the sequence of PKCa
between the NcoI site (position 50) and the XmaIII site (position 68)
was substituted for a linker resulting from the annealing of the two fol-
lowing oligonucleotides: sense, CATGGCTCATCACCATCATCAC-
GACGTCTTCCC; antisense, GGCCGGGAAGACGTCGTGATGGT-
GATGGTGATGAGC. The nucleotide sequence encoding N-His PKCa
was subcloned into the pKS1 [37] vector as a SacII–XhoI fragment.
Mutations were introduced in the bovine PKCa cDNA using the
Altered Sites in vitro mutagenesis system (Promega). An EcoRI–XbaI
fragment containing the full coding sequence of PKCa was cloned into
the pAlter-1 vector. In addition to the ampicillin repair oligonucleotide,
the following mutagenic oligonucleotides, which are sense with respect
to the PKCa cDNA, were used (changed bases are underlined):
T497E, ATGGACGGCGTCACGACCAGGGAGTTCTGCGGGACC;
T494A/T495A/T497E, ATGGACGGCGTCGCGGCCAGGGAGTTC-
TGCGGGACC; T638A, GGGCAGCCTGTCTTGGCGCCGCCC-
GACCAGCTG; T638E, GGGCAGCCTGTCTTGGAGCCGCCCGA-
CCAGCTG.
Mutant sequences were validated by sequence analysis using the
Sequenase version 2.0 DNA sequencing kit (USB). Either a
Bal1–Xba1 fragment (corresponding to amino acids 17–672) or a
Sma1–Xba1 fragment (corresponding to amino acids 578–672) from
pAlter-1 plasmids containing the different PKCa mutants, were ligated
to a pKS1-N-His PKCa plasmid, restricted with the corresponding
enzymes, in order to create the different pKS1-N-His PKCa construct.
Purification of PKCa after transient expression in COS-1 cells
COS-1 cells were maintained in Dulbecco’s modified Eagle’s medium
containing 10 % (v/v) fetal-calf serum, 1000 units ml–1 penicillin and
100 mg ml–1 streptomycin. 50 mg plasmid pKS1, or pKS1-N-His
PKCa, encoding wild-type or mutant PKCa proteins, was introduced
into 0.8 ml of 60–80 % confluent COS-1 cells (5 × 106 cells) by elec-
troporation (0.45 kV for 8–10 msec) . After 48 h of transient expres-
sion, the cells were lysed in 500 ml of an ice-cold lysis buffer containing
20 mM Tris–HCl (pH 7.5), 120 mM NaCl, 1 % (v/v) Triton X-100, 
2 mM b-mercaptoethanol, 5 mM benzamidine, 50 mg ml–1 leupeptin,
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50 mg ml–1 aprotinin, 50 mg ml–1 trypsin inhibitor, 5 mg ml–1 pepstatin,
1 mM phenylmethysulfonyl fluoride, 20 mM NaF, 1 mM Na3VO4, 1 mM
para-nitrophenylphosphate and 5 mM imidazole. The suspension was
subjected to 20 strokes in a Dounce homogenizer and centrifuged at
12 000 × g for 30 min at 4 °C. The supernatant (Triton-soluble extract)
was tumbled for 1 h at 4 °C after adding 30 ml of a nickel–
NTA–agarose slurry (nickel–agarose) (Qiagen). After a short spin, the
supernatant (unbound material) was removed and the beads (bound
material) were washed 3–5 times in 500 ml of lysis buffer. The last
pellet was finally tumbled for 1 h at 4 °C in 500 ml of lysis buffer (1 %
Triton for Fig. 3, 0.02 % Triton otherwise) containing 100 mM imida-
zole, in order to elute the histidine-tagged PKC from the beads. The
Triton-soluble and Triton-insoluble fractions were mixed with 5×
Laemmli buffer [40] and subjected to SDS–PAGE.
Treatment of COS-1 cells with phorbol esters
Plasmid DNA was introduced into COS-1 cells as described above.
After 30h of transient expression, the medium was changed and
500 nM TPA was added. At various time points, the incubation medium
was removed, cells were quickly rinsed in ice-cold PBS and lysed in
lysis buffer (same as above but without imidazole) supplemented with
10 mM microcystin. The lysate was passed twice through a 27-gauge
needle and centrifuged for 20 min at 12 000 × g at 4 °C.
Treatment of purified PKC with PP1
The g isoform of PP1 [38] was obtained as a recombinant protein after
introduction of the pCW PP1 plasmid into competent Escherichia  coli
DH5a. Expression and purification were carried out as described in
[39]. The final fractions, containing phosphatase activity, were pooled,
dialysed overnight at 4 °C against 25 mM triethanolamine–HCl
(pH 7.5), 0.02 % (v/v) Triton X-100, 1 mM MnCl2, 2 mM b-mercap-
toethanol, 50 % (v/v) ethyleneglycol, and stored at –20 °C. For PKC
samples to be subjected to PP1 treatment, the last washing and the
elution steps (see above) were performed in the absence of NaF,
Na3VO4 and para-nitrophenylphosphate. Treatment of PKC with PP1
took place at 22 °C with PKC either bound to (Fig. 5) or eluted from
(Fig. 8b) nickel–agarose, in the presence of 1 mM MnCl2. The reaction
was stopped by adding 10 mM microcystin.
Protein assays and analysis
For determination of PKC activity, each PKC sample (10 ml) was mixed
with 30 ml of a solution containing 5 mM Hepes, 0.2 % Triton X-100,
150 mM KCl, 2 mM MgCl2, 2 mg ml–1 substrate (histone III-S, or prota-
mine sulfate) and 200 mM g-[32P]ATP. After 3 min at 25 °C, 20 ml of the
mixture was removed and spotted on P81 phosphocellulose filters
(Whatman). Filters were washed three times in 30 % acetic acid and
counted. When histone III-S was used as a substrate, Triton X-100 was
present as mixed micelles containing 1 mg ml–1 TPA and 1 mg ml–1 phos-
phatidylserine, in the presence of 0.1 mM CaCl2 (final concentrations). 
Protein concentrations were determined by the bicinchoninic acid
method (Pierce Chemical Co.), using bovine serum albumin as the
standard. SDS–PAGE was performed on samples diluted twice in 5×
Laemmli buffer [40], using 12 cm long running gels containing 7.5 %
acrylamide and 0.06 % bisacrylamide, except for Fig. 1 (10 % acry-
lamide, 0.27 % bisacrylamide) and Fig. 7 (12.5 % acrylamide, 0.33 %
bisacrylamide). When required, the gel was transferred onto nitrocellu-
lose, and subjected to immunoblotting using a polyclonal antibody
raised against the carboxyl terminus of PKCa [41]. The secondary (per-
oxidase-linked donkey anti-rabbit) antibody as well as the ECL western-
blotting detection system were from Amersham. All reproductions of
gels and autoradiographies were obtained as computer-scanned
images.
Limited proteolysis of wild-type and A638 PKCa was carried out using
10 mg ml–1 trypsin at 30 °C, in a final volume of 30 ml containing
20 mM Tris–HCl (pH 8.0), 15 mM b-mercaptoethanol, 0.5 mM micro-
cystin, 0.02 % (v/v) Triton X-100 and 0.6 units of PKCa. Proteolysis
was terminated by adding 10 ml of 0.4 mg ml–1 trypsin inhibitor.
Samples were subsequently boiled in 0.3 volumes of 4× sample buffer
and then subjected to SDS–PAGE.
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